Best Viral Vector CDMOs in Switzerland
· updated as new inspection, certificate, and trial data enters the platform
6
CDMOs tracked
5
Fully scored
3
With FDA records
7
FDA inspections
27
EMA/MHRA GMP certs
Viral vector CDMOs manufacture the three GMP-relevant vector platforms used in modern gene therapy and gene-modified cell therapy: adeno-associated virus (AAV), lentivirus, and adenovirus. Each platform has distinct process, containment, and analytics requirements, and CDMOs typically specialize in one or two platforms rather than all three. Platform is the first shortlist filter in any viral vector procurement decision.
This ranking aggregates every CDMO tracked as a viral vector manufacturer across the three platforms. For platform-specific rankings with process-critical detail (BSL-2 containment for lentivirus, full/empty capsid analytics for AAV, high-titre transient expression for adenovirus), use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors integrating vector supply with downstream cell processing (CAR-T, gene-modified HSC), the <a href="/modality/cell-and-gene-therapy">cell & gene therapy view</a> extends this list with cell therapy CDMOs.
FDA inspection outcomes across these CDMOs: 2 NAI (no action), 5 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Austria (9), United States (6), Ireland (5), Germany (4), UNITED KINGDOM (3).
Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
TK
Takeda
Boston, MA · Zurich, CH
|
80.5 | 99.3 | 4 insp · 18 GMP | — | 100 programs |
| 2 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 2 insp · 8 GMP | — | 1 programs |
| 3 |
CE
Celonic
Basel, Switzerland
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 4 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
72.8 | 95.1 | 1 insp · 0 GMP | Limited | 0 programs |
| 5 |
DINAMIQS
Schlieren (Zurich), Switzerland
|
59.0 | — | — | Available | 0 programs |
| — |
Roche / Genentech (Internal Manufacturing & CustomBiotech)
Basel, Switzerland
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Viral Vector CDMO
Vector platform match
First shortlist filter for any viral vector program is platform. AAV for in vivo systemic, lentiviral for ex vivo cell engineering, adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within.
Facility-level regulatory record on the platform
A CDMO's strong FDA record on AAV does not automatically de-risk their lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use, not the CDMO's aggregate score.
Analytics maturity per vector
Full/empty capsid separation for AAV, RCL testing for lentivirus, particle-to-infectivity ratio for adenovirus — each platform has non-negotiable release-testing requirements. A CDMO's qualified, validated assay panel for the specific vector is the single most under-appreciated cost driver in viral vector programs.
Capacity match to phase and dose
AAV early clinical runs at 50-200L, commercial at 1,000-2,000L single batch; lentiviral commercial supply is a narrower field with per-patient-dose economics. Confirm the CDMO's capacity headroom at your target phase before shortlisting — capacity constraints appear late and derail commercial launches.
Why are Swiss CDMOs positioned as premium-tier for biopharma manufacturing?
The Swiss CDMO cluster (Basel, Visp, Bern) hosts three attributes that reinforce a premium tier positioning: (1) regulatory alignment — Switzerland's Swissmedic runs a mutual-recognition GMP framework with the EU, so a Swiss facility supplying the EU doesn't need parallel EMA certification for the same activities; (2) technical depth — Swiss CDMOs have historically led on complex chemistry (Lonza on biologics + peptides, Bachem on peptides, CordenPharma on APIs) and on early-adopter viral vector manufacturing; (3) capital access — Swiss operations are able to make sustained capex investments in single-site scale-ups that lower-cost jurisdictions cannot match. That said, Swiss CDMOs also carry higher per-batch costs than Asian or Eastern European alternatives — the trade-off is process depth and regulatory posture, not price.
How does Switzerland's non-EU status affect drug supply to EU markets?
Switzerland is not an EU member state but maintains a bilateral Mutual Recognition Agreement (MRA) with the EU covering GMP inspections. Practically: a Swissmedic GMP inspection is recognized by EMA as equivalent to an EMA GMP inspection for the covered activity. Swiss-manufactured product does still require an EU-based Qualified Person for batch release into the EU market, but the facility itself does not need parallel EMA certification. This makes Swiss CDMOs operationally cleaner for pan-European supply than most non-EU alternatives. For UK supply, post-Brexit MHRA has continued to recognize the Swissmedic MRA under transitional arrangements — sponsors supplying both EU and UK should confirm current MHRA policy at RFP stage.
Which Swiss CDMOs are also present in the US and Asia?
The largest Swiss CDMOs — Lonza, CordenPharma, Bachem — operate global site networks spanning Switzerland, US, and (in Lonza's case) multiple Asian geographies. This multi-region posture materially reduces regulatory tech-transfer risk for programs supplying multiple markets from a single CDMO relationship. Cross-check with the US region ranking and Asia region ranking to identify Swiss-headquartered CDMOs with cross-jurisdictional footprint. Individual profile pages surface the specific site network.
Viral Vector CDMOs — Frequently Asked Questions
Who are the top Viral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Viral Vector CDMOs include Takeda, Lonza, Celonic. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Viral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 3 Viral Vector CDMOs with FDA inspection records and 27 EMA/MHRA GMP certificates across the group.
What should I look for in a viral vector CDMO?
Match the vector platform first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, vector-specific analytics maturity, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific technical detail worth reading before finalizing a shortlist.
How many viral vector CDMOs does CDMO Signal track?
65+ CDMOs are tracked across the three GMP viral vector platforms — the union of AAV, lentiviral, and adenoviral manufacturers, deduplicated. Each is scored independently on the standard four-pillar Signal Score composite.
How is viral vector manufacturing different from mAb or recombinant protein biologics?
Viral vector manufacturing shares the mammalian cell culture upstream backbone with biologics but diverges sharply on downstream. Viral vector downstream requires enveloped/non-enveloped virus purification (chromatography, tangential flow filtration, ultracentrifugation) rather than protein A affinity capture. Analytics differ fundamentally — infectious titer and capsid analytics for viral vectors vs product-related impurities for biologics. Regulatory paths also differ: viral vectors carry additional biosafety review (RCL for lentivirus, adventitious agents for all platforms) beyond standard biologics.
Related modalities